Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
glumetinib + fruquintinib
- Development stage
- Unknown
- Lead developer
- HUTCHMED
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**Glumetinib + fruquintinib** is an investigational oral, small molecule combination therapy evaluated for use in advanced colorectal cancer, specifically in tumors with MET amplification or overexpression. Glumetinib is a selective inhibitor of the MET receptor tyrosine kinase, targeting pathway(s) involved in cancer cell proliferation and survival. Fruquintinib is an oral, highly selective inhibitor of vascular endothelial growth factor receptors VEGFR-1, VEGFR-2, and VEGFR-3, blocking angiogenesis required for tumor growth. The rationale behind this combination is to simultaneously inhibit tumor angiogenesis (via VEGFR) and tumor cell proliferation and survival pathways (via MET), potentially providing synergistic antitumor effects in cancers exhibiting both MET activation and angiogenic activity[1][5].
- Brand names
- GulinanElunate
- Other names
- SCC-244SCC244SCC 244HMPL013HMPL-013HMPL 013
02
Targets
VEGFR3 (Vascular endothelial growth factor receptor 3)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)MET (Mesenchymal-epithelial transition factor receptor)
Beyond the preview
Go deeper on glumetinib + fruquintinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on glumetinib + fruquintinib.